Used in Over 45,000 Beds, Break-Even Expected in Second Half of 2025… Accelerating Global Market Expansion

AITRICS(CEO Kwang joon Kim), a company specializing in artificial intelligence (AI) technology announced on the 21st that the number of medical institutions billing after adopting the patient deterioration prediction AI solution 'AITRICS-VC (VitalCare)' has surpassed 100.

AITRICS-VC is a solution that accurately predicts the risk of the following within a short timeframe: ▲ Acute critical events (death, ICU transfer, cardiac arrest) within 6 hours in general wards ▲ Sepsis within 4 hours in general wards ▲ Risk of death within 6 hours in intensive care units

Since entering the non-reimbursed market in March 2023, AITRICS-VC has been used in approximately 45,000 beds across 100 hospitals in Korea as of April 2025, supporting rapid clinical decision-making by medical staff. In particular, with its adoption expanding to major medical institutions including tertiary hospitals, the cumulative number of beds is rapidly increasing. Additionally, preliminary procedures for adoption are currently underway in about 20 hospitals.

AITRICS-VC is operated on a pricing model that charges per bed per day in proportion to actual usage. Within two years of its launch, it has become a key solution driving AITRICS’ main revenue. The company forecasts breaking even in the second half of 2025, based on AITRICS-VC’s stable revenue structure.

In 2024, AITRICS recorded annual sales of approximately 10 billion KRW through AITRICS-VC. This year, the company plans to strengthen its leadership in the market by expanding its portfolio into various medical settings such as emergency departments, alongside increasing the number of domestic beds, and also plans to accelerate overseas expansion. In particular, AITRICS-VC obtained FDA 510(k) clearance in the United States last year and is currently preparing clinical research with local medical institutions.

Kwang-joon Kim, CEO of AITRICS said, “AITRICS-VC continues to provide real value to both medical staff and patients, and these outcomes are leading to meaningful revenue results,” adding, “We will faithfully accumulate clinical evidence through the non-reimbursed use of AITRICS-VC under the New Health Technology Assessment deferment system, and further strive to secure institutional credibility based on actual results in the medical field.”